Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?
- 18 February 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Oncology
- Vol. 20 (1), 70-81
- https://doi.org/10.1007/s10147-014-0672-8
Abstract
The neutrophil-to-lymphocyte ratio (NLR) is a strong predictor of mortality in patients with cancer. Similarly, a study in a large series has shown that the newly defined derived NLR (dNLR; neutrophil/leukocyte–lymphocyte ratio) also has prognostic value. The present study retrospectively evaluates the prognostic significance of NLR and dNLR in breast cancer.Keywords
This publication has 35 references indexed in Scilit:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals Of Oncology, 2013
- The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinomaEuropean Journal Of Cancer, 2012
- Neutrophils cascading their way to inflammationTrends in Immunology, 2011
- Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancerBritish Journal of Cancer, 2011
- The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome StudyBritish Journal of Cancer, 2010
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009Annals Of Oncology, 2009
- Cancer-related inflammationNature, 2008
- Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancerBritish Journal of Cancer, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancerBritish Journal of Cancer, 2006